Metabolomics refers to the study of the whole set of metabolites in a biological sample that constitute a reflection of cellular functions. Cancer cells display significantly altered cellular processes, and thus metabolites, compared to normal cells. This can be detected in a number of ways, and is already exploited to a limited extent in the diagnosis of cancer. The host response to the tumor is perhaps equally important, as it either rejects or permits tumor growth, and this may also potentially result in a measurable metabolite signature. Analysis then of entire pools of metabolites may yield critical information about both tumor presence and host response, and represent a possible novel collective biomarker for cancer behaviour that could allow prediction of relapse, response to therapy, or progression. Isolating meaningful differences in the sea of metabolites and within the context of significant metabolic heterogeneity both within and between patients remains a great challenge. This chapter will review current metabolomic research in breast cancer, with a focus on efforts to translate the technology into clinical practice.
Keywords: Biomarker; Breast cancer; Metabolic profile; Metabolomics; Prognostics; Risk prediction.